Praxis Precision Medicines, Inc. · NASDAQ:PRAX
Praxis Precision Medicines — Corporate Update (March 2021)
7 slides from Praxis Precision Medicines's corporate update, Mar 17, 2021
Slide 1: 4Q/FY 2020 Corporate Update
Exhibit 99.2 4 Q / F Y 2 0 2 0 CORPORATE UPDATE M A R C H 2 0 2 1 CONFIDENTIAL P PAGE AGE 1 1Exhibit 99.2 4 Q / F Y 2 0 2 0 CORPORATE UPDATE M A R C H 2 0 2 1 CONFIDENTIAL P PAGE AGE 1 1
Slide 2: Forward-looking statements
Forward-looking statements This presentation has been prepared by Praxis Precision Medicines, Inc. (“we,” “us,” “our,” “Praxis” or the “Company”) and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be a
Slide 3: PRAX-114 Phase 2/3 monotherapy MDD trial to start March 2021
PRAX-114 Phase 2/3 monotherapy MDD trial to start March 2021 PHASE 2/3 WEEK 1 2 3 4 5 6 OUTPATIENT NIGHTHLY DOSING FOLLOW-UP First of two registrational trials for monotherapy MDD Ph 2/3 1:1 RANDOMIZED PLACEBO - 114 40 mg tablet CONTROLLED IN MONOTHERAPY MDD PLACEBO KEY INCLUSION CRITERIA ~200 Subje
Slide 4: PRAX-114 clinical program leverages best practices in conduct of MDD trials
PRAX-114 clinical program leverages best practices in conduct of MDD trials Key Operational Controls 1 • Enrollment of patients with at least one prior episode of MDD (associated with a lower placebo response rate) 2 RIGOROUS PATIENT • Two-level subject & data quality procedure using the SAFER indep
Slide 5: PRAX-944 Phase 2a low dose cohort tremor reduction data compares favorably with standard-of-care
PRAX-944 Phase 2a low dose cohort tremor reduction data compares favorably with standard-of-care Change from Baseline in TETRAS Score Percent Change in Tremor Amplitude PERFORMANCE SCALE (PS) UPPER LIMB (UL) PERFORMANCE SCALE (PS) UPPER LIMB (UL) ON TREATMENT WASHOUT ON TREATMENT WASHOUT CONFIDENTIA
Slide 6: PRAX-944 Phase 2a high dose cohort clinical trial design
PRAX-944 Phase 2a high dose cohort clinical trial design PART B: Open-Label Titration & Randomized Withdrawal Study — Up to 12 patients, up to 120 mg 1:1 Days 1-28 Days 29-42 Randomization Stable Period Screening Open-Label Titration of PRAX-944 at High Dose Randomized Withdrawal (Days 43-56) PRAX-9
Slide 7: Substantial potential for value creation across the portfolio
Substantial potential for value creation across the portfolio Mood Disorders Movement Disorders Rare Diseases Indication PRAX-114 PRAX-944 PRAX-562 Preclinical Expansion Depression Essential Tremor Rare Diseases Genetically Defined Epilepsies Multiple indication GABA receptor PAM T-type calcium Sele
Praxis Precision Medicines — Corporate Update (March 2021) on 6ix